

1 Molecular subtypes of respiratory Adenovirus infection outbreak in children in Northern
2 Vietnam and risk factors of more severe cases

3
4 Dinh-Dung Nguyen¹, Lan Tuyet Phung^{2,3}, Huyen Thi Thanh Tran¹, Ha Thi Thanh Ly¹, Anh Hang Mai Vo¹,
5 Nhung Phuong Dinh¹, Phuong Mai Doan⁴, Anh Thi Nguyen⁴, Luc Danh Dang⁴, Thia Thi Doan⁴, Khuong Thi
6 Pham², Huong Lan Pham², Dai Hoang Xuan², Thao Phuong Nguyen³, Bao Thai Tran³, Trang Thi Thuc Tran³,
7 Huong Thi Minh Le², An Nhat Pham², Antony Antoniou⁵ and Nhan Thi Ho⁶

8 ¹Medical Genetics Department, Center of Applied sciences, Regenerative medicine and Advance
9 Technologies, Vinmec Healthcare System

10 ² Pediatric Center, Vinmec International General Hospital in Hanoi

11 ³ VinUniversity

12 ⁴ Microbiology Lab, Laboratory Department, Vinmec International General Hospital, Hanoi

13 ⁵Department of Applied Sciences, Faculty of Health and Life Sciences, Northumbria University, Newcastle
14 upon Tyne, United Kingdom

15 ⁶ Research & Development Department, Center of Applied sciences, Regenerative Medicine and Advance
16 Technologies, Vinmec Healthcare System

17

18

19 Abstract

20 **Background:** Under the pressure of the outbreak of respiratory Human Adenovirus (HAdV) infections in
21 children in Northern Vietnam in the end of 2022, this study was initiated to identify the HAdV subtype(s)
22 responsible for the outbreak in relation to the clinical features of the patients and examine the risk factors
23 of more severe cases.

24

25 **Methods:** The study was conducted on pediatric patients tested positive with HAdV using multiplex real-
26 time PCR between October and November 2022. Nasal swab samples were used for sequencing to identify
27 HAdV subtypes and clinical data were collected retrospectively.

28

29 **Results:** Among 97 successfully sequenced samples, the predominant subtypes were HAdV-B3 (83%),
30 HAdV-B7 (16%) and HAdV-C2 (1%). Lower respiratory manifestations were found in 25% of patients (5%
31 with severe pneumonia). There was no significant association between HAdV type and clinical features
32 except that those infected with HAdV type 3 exhibited higher WBC and neutrophil % ($p < 0.001$). Co-
33 infection of HAdV with ≥ 1 other respiratory viruses or bacteria was found in 70.8% of those with lower
34 respiratory illnesses (OR (95%CI); p -value vs. those without = 5.21 (1.60, 19.36); 0.0084 after adjusting for
35 age at hospital visit, sex, birth delivery method, day of disease at hospital visit), and in 100% of those with
36 severe pneumonia vs. 33% of those without ($p = 0.005$).

37

38 **Conclusion:** HAdV-B3 and HAdV-B7 were predominant in the outbreak. Co-infection of HAdV together
39 with other respiratory viruses or bacteria was a strong risk factor for lower respiratory tract illnesses and

40 severe pneumonia. The findings advocate the advantages of multi-factor microbial panels for the
41 diagnosis and prognosis of respiratory infections in children.

42

43

44

45

46

47

48

49 Introduction

50 Human Adenoviruses (HAdV) can cause many common diseases such as upper respiratory infection,
51 conjunctivitis, gastrointestinal disorders, etc. HAdV consists of many serotypes, which are responsible for
52 different disease contexts (1).

53 There had been some sporadic HAdV outbreaks with respiratory illnesses, conjunctivitis, and
54 gastrointestinal disorders worldwide before the COVID-19 era. Respiratory illnesses were reported in
55 most of these studies, and HAdV infections with severe respiratory illnesses in children had been reported
56 in some studies (3–26). The most prevalent respiratory HAdV reported in children in Taiwan were HAdV-
57 B genotype 3 and HAdV-C (HAdV-2), and 7 (15,24,26), in China were HAdV-B3 and HAdV-C2, and 7
58 (9,10,12,17,27), in Japan were HAdV type 3, 2, and 1 (21), in Argentina were HAdV-B7 and HAdV-B3
59 (16,20), in Spain were HAdV-3, HAdV-6, and HAdV-5 (25), in Egypt were type 3 and 7 (28), in Palestine
60 were HAdV-C1, HAdV-C2, HAdV-B3 and HAdV-C5 (6). HAdV type 7, 3, and 2 were the most common types
61 which were associated with severe respiratory illnesses in children, especially in those with underlying
62 diseases or immunocompromised conditions (10–12,16–19). During the early stages of the COVID-19
63 pandemic with social distancing until 2021, respiratory tract infections in children including HAdV
64 infections exhibited a remarkable decrease in occurrence (14,29–31).

65 In Vietnam, there have been some reports of adenoviral conjunctivitis (32,33), and gastroenteritis
66 (13,34,35). HAdV is among the less common viral causes of seasonal respiratory infections as compared
67 to many other more common viruses such as influenza, parainfluenza, respiratory syncytial virus (RSVs),
68 enteroviruses, rhinovirus, etc (36–43). HAdV is among the co-infection factors in patients with severe
69 pneumonia (39). HAdV pneumonia especially type 7 has been reported to be among the causes of death
70 in patients following measles infection (44,45). There has not been any information regarding respiratory
71 HAdV outbreaks in children in Vietnam until the first half of 2022.

72 Since the second half of 2022, HAdV had emerged as the cause of the outbreak of respiratory infections
73 in children in Northern Vietnam. Whilst most of the cases were mild, there had been a considerable
74 number of cases with severe complications such as pneumonia, acute respiratory distress. which required
75 intensive treatment and prolonged hospitalization. In addition, quite a few deaths attributed to HAdV
76 infection had been reported. While the COVID-19 pandemic had been somewhat under control, the
77 outbreak of respiratory HAdV infection in children in Northern Vietnam with a large number of cases and
78 an alarming number of severe cases and deaths was unprecedented and thus especially worrisome and
79 required immediate actions.

80 Up till now, in Northern Vietnam, the diagnosis of HAdV infection was confirmed by positive PCR of nasal
81 swabs performed by a few centers. However, molecular typing of HAdV had not been performed to
82 identify the HAdV subtype(s) responsible for the outbreak, especially in severe or fatal cases. As such, this
83 study aimed to perform molecular typing of HAdV and examine the relationship between HAdV types and
84 clinical contexts of children with respiratory HAdV infections in Northern Vietnam to understand the
85 characteristics of the pathogen in relation to host characteristics. The study also examined potential risk
86 factors for the severity of the diseases to help orientate the treatment and prognosis of the patients.

87

88 [Materials & Methods](#)

89 [Sample Collection](#)

90 This study was done in Vinmec Times City International Hospital, a private general hospital in Hanoi
91 Vietnam which receives patients mostly from Hanoi and surrounding provinces. The study was approved
92 by the hospital's ethical committee before being carried out (Reference number: 152/2022/CN-HDDD
93 VMEC).

94 Nasopharyngeal wash or swab samples of pediatric inpatients and outpatients with respiratory symptoms
95 suspected of Adenoviral infection were collected in a 15.0 ml centrifuge tube and transported to the
96 Department of Microbiology. Specimens were stored at 4°C and partly used to extract RNA by QIAamp
97 Viral RNA Kits (QIAGEN, German) within 24 hours after collection. Extracted RNA samples were tested for
98 HAdV and 6 other respiratory pathogens (human enterovirus (HEV), human metapneumovirus (hMPV)
99 and parainfluenza virus 1-4 (PIV1-4)) using multiplex real-time PCR Allplex™ Respiratory Panel 2 (Avicalab
100 Diagnostics, Kenya) according to the manufacturer's instruction (46,47). Samples with quantification cycle
101 (Ct) value < 38 were considered HAdV-positive.

102 The leftover nasopharyngeal samples (NS) of those with HAdV-positive PCR were stored and transported
103 to Vinmec Medical Genetic Department for further processing to perform HAdV molecular typing. To
104 ensure a sufficient DNA concentration for sequencing and to minimize possible artifacts due to
105 contamination, only samples with Ct for HAdV <30 were selected for molecular typing.

106 For pediatric patients with HAdV-positive PCR, clinical data regarding medical history especially prior to
107 COVID infection, clinical manifestations, lab tests (hematology, biochemistry and also nasal-pharyngeal
108 swab culture, PCR panel for 7 respiratory bacteria, blood *Mycoplasma pneumoniae* Antibody test,
109 influenza antigen rapid test if available), treatments, outcomes, etc were retrospectively collected by
110 Vinmec Pediatric Center. These data were entered and managed in RedCap ([https://www.project-](https://www.project-redcap.org/)
111 [redcap.org/](https://www.project-redcap.org/)).

112 All patients included in this study had respiratory symptoms such as cough, runny nose, etc. Patients were
113 classified as having lower respiratory illnesses if having lower respiratory symptoms such as rales, rhonchi,
114 wheezing, etc or having lesions in chest x-ray. Patients were classified as having severe pneumonia if
115 having signs of pneumonia clinically and/or in chest x-ray and respiratory distress.

116 Viral co-infection was defined if a patient with HAdV-positive PCR was also positive with at least one virus
117 in the PCR panel or in the influenza antigen rapid test.

118 Bacterial co-infection was defined if a patient with HAdV-positive PCR was also positive with at least one
119 bacteria in nasopharyngeal fluid culture or in a PCR panel of 7 respiratory bacteria (*H. influenzae*, *S.*
120 *pneumonia*, *S. aureus*, *M. catarrhalis*, *M. pneumoniae*, *C. pneumoniae*, *L. pneumoniae*) or in blood
121 *Mycoplasma pneumoniae* antibody test.

122 Any co-infection was defined if a patient had either a viral or bacterial co-infection as described above.

123 *HAdV molecular typing*

124 The hyper-variable regions 1-6 (HRV₁₋₆) of HadV exon are known to contain type-specific epitopes,
125 therefore, these sequences are commonly used to identify HAdV subtypes responsible for the diseases.

126 HAdV molecular typing was performed on 97 HAdV-positive samples. Viral nucleic acids were extracted
127 from NS using QIAamp DNA Blood Mini Kit (QIAGEN, Germany). Following the protocol recommended by
128 CDC, the *hexon* of HadV was amplified using nested PCR targeting the HVR₁₋₆ and amplicons were
129 expected to have the size between 764-896 base pairs (bp) (48). The outer primer pairs used for 1st round
130 of nested-PCR were AdhexF1 (5'- TICTTTGACATICGIGGIGTICTIGA-3') and AdhexR1 (5'-
131 CTGTCIACIGCCTGRTTCCACA-3'). The inner primer pairs used for 2nd round of nested-PCR were AdhexF2
132 (5'- GGYCCYAGYTTYAARCCCTAYTC-3') and AdhexR2 (5'- GGTCTGTC ICCAGAGARTCIAGCA-3'). Nested-
133 PCR was performed using a final concentration of 1x GoTaq Green Master Mix (Promega), 0.4 µM of each
134 primer, 2.0 µl of extracted viral nucleic acid or 0.2 µl of 1st nested-PCR product, and made up to a final
135 volume of 25 µl with double distilled water. The PCR thermal program for both rounds of nested-PCR
136 reactions were comprised an initial denaturation step at 94°C for 2 min, followed by 11 touched-down
137 cycles of 95°C for 30 sec, 55°C (decrease 1°C after each cycle) for 45 sec, 72°C for 1 min, followed by 20
138 thermal cycles of 95°C for 30 sec, 45°C for 45 sec, 72°C for 1 min, and a 5 min final extension at 72°C. The

139 size of PCR products were checked by DNA electrophoresis analysis on 1% agarose gels stained with
140 RedSafe DNA Stain (20,000 X) (Chembio, USA). Only samples with a detectable appropriate PCR product
141 from nested-PCR were used for Sanger Sequencing of the HVR₁₋₆ of hexon gene.

142 Each nested-PCR product was sequenced using both forward AdhexF2 and reverse AdhexR2 primers.
143 Sequencing PCR reactions were performed in a final volume of 10 µl comprising 0.5 µl of BigDye
144 Terminator v3.1 Cycle Sequencing (ABI), 2.0 µl of Sequencing Buffer 5X, 0.85 µl (10 µM) of primer, 0.2µl
145 2nd nested-PCR product, and distilled water (up-to-10 µl). The sequencing thermal cycle for sequencing
146 reactions were comprised of an initial denaturation step at 96°C for 2 min, followed by 25 thermal cycle
147 of 95°C for 10 sec, 50°C for 10 sec, and 60°C for 2 min. Cycle sequencing products were purified by Bigdye
148 X Terminator purification kit before analysis on th Applied Biosystems 3500 Dx Genetic Analyzer.

149 *Data analysis*

150 **Sequence data and phylogenetic analysis**

151 The sequence data were used to identify the subtype of HAdV by Basic Local Alignment Search Tool
152 (BLAST) search (NCBI). The sequences of HVR₁₋₆ of *hexon* gene from all samples were aligned with related
153 reference strains obtained from Genbank (reference strains are listed in Supplementary Table 1) using
154 ClustalW. The robustness of the phylogenetic tree was constructed by the neighbor-joining method with
155 bootstrap analysis (n = 1000) by iTOL v6 and Adobe Illustrator software. The cut-off value is <80%.

156 **Analysis of HAdV types and clinical contexts**

157 HAdV types and other clinical features were compared between disease contexts such as lower
158 respiratory illnesses vs. no lower respiratory illnesses or severe pneumonia vs no severe pneumonia. The
159 purpose was to examine if HAdV type or any other clinical features were associated with the severity of
160 HAdV infection. Clinical features were also compared between HAdV types to examine if any clinical
161 characteristic was associated with HAdV types.

162 For comparison between groups for initial association exploration, Kruskal-Wallis was used for
163 continuous variables and Fisher's exact test was used for categorical variables.

164 Potential risk factors for lower respiratory illnesses or severe pneumonia which were clinically relevant or
165 statistically significant from the above exploration were further examined using univariate and
166 multivariate logistic regression models. Unadjusted and adjusted odds ratio (OR) and 95% confidence
167 interval (95%CI) by profile likelihood and p-values from Wald test were reported.

168 Data analysis was done using R statistical software version 4.1 (<https://www.r-project.org>). All statistical
169 tests were 2-sided with a significant level alpha of 0.05.

170

171 Results

172 *Patient characteristics and clinical features*

173 From October 13th to November 9th, 2022, 138 patients tested positive for HAdV using a Q-PCR assay
174 from nasal swabs. Among these, 97 patients with Ct for HAdV <30 were selected for molecular typing. Of
175 these 97 samples, the median (IQR) Ct of HAdV was 23.6 (21.9, 25.6).

176 Patient characteristics overall and comparison between those with and without lower respiratory illnesses
177 and those with and without severe pneumonia are summarized in Table 1. About 68% of patients resided
178 in Hanoi and 32% resided in surrounding provinces. About 29% reported history of prior COVID-19
179 infection. About 4% reported history of allergy and about 7% reported history of prior severe respiratory
180 diseases. There were 73 (75%) patients with only upper respiratory symptoms whilst there were 24 (25%)
181 with lower respiratory manifestations of which 5 (5.1%) had severe pneumonia. There were no differences
182 in demographic and previous history of respiratory disease including COVID19 infection between those
183 with and without lower respiratory illnesses in these characteristics (Table 1, Figure 1, Figure 2).


184 **Table 1. Patient characteristics overall and in groups with lower respiratory illnesses and severe**
 185 **pneumonia.**

Characteristics	All patients (N=97)	Group with lower respiratory illnesses (N=24)	P-value comparison*	Group with severe pneumonia (N=5)	P-value comparison #
HAdV type	Type 3= 81(84%); Type 7= 15 (15%); Type 2= 1 (1%)	Type 3= 19 (79.2%); Type 7= 5 (20.8%); Type 2=0	0.636	Type 3= 4 (80.0%); Type 7= 1 (20.0%); Type 2=0	0.602
Viral co-infection\$	20 (20.6%)	12 (50.0%)	< 0.001	4 (80.0%)	0.006
Bacterial co-infection @	20 (20.6%)	7 (29.2%)	0.253	3 (60.0%)	0.058
Any co-infection \$@	35 (36.1%)	17 (70.8%)	< 0.001	5 (100.0%)	0.005
Sex (males)	53 (55.8%)	13 (54.2%)	1	4 (80.0%)	0.379
Age at hospital visit (mean (95%CI))	2.7 (2.4, 3.1)	2.3 (1.6, 2.9)	0.141	1.8 (0, 3.8)	0.190
BMI (kg/m ²) (mean (95%CI))	15.3 (14.9, 15.6)	15 (14.2, 15.9)	0.497	14.7 (13.7, 15.7)	0.487
Gestational age (week) (mean (95%CI))	37.6 (36.8, 38.5)	37.8 (36.9, 38.7)	0.517	36 (36, 36)	0.115
Delivery method	C-section= 27 (35.5%); Vaginal= 49 (64.5%)	C-section= 11 (50.0%); Vaginal= 11 (50.0%)	0.116	C-section= 4 (80.0%); Vaginal= 1 (20.0%)	0.051
Breast feeding duration (month) (mean (95%CI))	12.1 (10.9, 13.3)	13.2 (10.8, 15.6)	0.410	12.3 (2.7, 21.8)	0.575
History of COVID-19 infection	18 (29.0%)	4 (26.7%)	1	1 (50.0%)	0.500
History of allergy	4 (4.3%)	1 (4.2%)	1	0 (0.0%)	1
History of immuno-compromise diseases	0	0	NA	0	NA
History of chronic disease	0	0	NA	0	NA
History of severe respiratory disease	7 (7.2%)	1 (4.2%)	0.677	1 (20.0%)	0.318
Day of disease at hospital visit (mean (95%CI))	3.6 (3.2, 4)	4.7 (3.7, 5.6)	0.002	4 (2, 6)	0.422
Cough	88 (95.7%)	23 (95.8%)	1	4 (80.0%)	0.203

Fever	88 (90.7%)	21 (87.5%)	0.685	5 (100.0%)	1.000
Duration of fever (day) (mean (95%CI))	6.2 (5.7, 6.8)	7.1 (5.7, 8.6)	0.125	6.2 (1.8, 10.6)	0.839
Red eye	30 (33.3%)	5 (21.7%)	0.207	0 (0.0%)	0.165
Loose stool	15 (16.7%)	6 (25.0%)	0.352	1 (20.0%)	1
Lymph node enlargement	6 (6.7%)	1 (4.2%)	1	0 (0.0%)	1
Skin rash	1 (1.1%)	0 (0.0%)	1	0 (0.0%)	1
Coughing up sputum	86 (93.5%)	22 (91.7%)	1	5 (100.0%)	1
Ear pain	5 (5.9%)	1 (4.3%)	0.653	0 (0.0%)	1
Abdominal pain	7 (7.9%)	2 (8.7%)	1	0 (0.0%)	1
Poor eating	38 (42.2%)	16 (66.7%)	0.007	4 (80.0%)	0.158
WBC (mean (95%CI))	15 (13.5, 16.5)	13.8 (10.9, 16.7)	0.295	13.5 (3.6, 23.5)	0.661
Neutrophil % (mean (95%CI))	61.2 (58, 64.4)	59.5 (52.4, 66.6)	0.659	64.5 (41.9, 87)	0.496
Lymphocyte % (mean (95%CI))	26.8 (23.8, 30)	29.9 (22.9, 36.9)	0.405	26.8 (4.8, 48.9)	0.766
Hemoglobin (g/L) (mean (95%CI))	85.5 (74.7, 96.3)	84.6 (64.2, 105)	0.364	89.1 (34.5, 143.7)	0.538
Platelet (mean (95%CI))	295 (275, 315)	304 (250, 357)	0.811	412 (183, 641)	0.104
CRP (mean (95%CI))	40.4 (32.8, 48.1)	41.3 (22.3, 60.3)	0.773	37.2 (0.5, 73.9)	0.949
Chest X-ray abnormality	22 (51.2%)	19 (95.0%)	< 0.001	5 (100.0%)	0.048
Duration of treatment (day) (mean (95%CI))	5 (4.5, 5.6)	6.1 (4.7, 7.4)	0.020	9.5 (4.9, 14.1)	0.003
Oxy supplement	6 (6.2%)	6 (25.0%)	<0.001	4 (80.0%)	< 0.001
Intravenous Immunoglobulin (IVIG) infusion for Adenovirus treatment	2 (2.9%)	2 (9.5%)	0.098	2 (40.0%)	0.004
Nebulizer	10 (14.3%)	10 (43.5%)	< 0.001	4 (80.0%)	0.001
Corticoid use	5 (7.4%)	5 (23.8%)	0.002	4 (80.0%)	< 0.001
Antibiotic use	78 (86.7%)	23 (95.8%)	0.170	5 (100.0%)	1.000
Clinical outcome	Dead=0 (0.0%); Discharged with complication =1 (1.2%); Discharged without	Dead=0 (0.0%); Discharged with complication = 1 (4.8%); Discharged without	0.6941	Dead=0 (0.0%); Discharged with complication = 1 (20.0%); Discharged without	0.0630

	complication = 82 (98.8%)	complication = 20 (95.2%)		complication = 4 (80.0%)	
--	------------------------------	------------------------------	--	-----------------------------	--

186 *Comparison between those with and without lower respiratory illnesses.
 187 #Comparison between those with and without severe pneumonia.
 188 P-values from Kruskal-Wallis test for continuous variables or Fisher's exact test for categorical variables.
 189 \$Co-infection with ≥ 1 other viruses in PCR panel or influenza virus type A or type B using rapid antigen test
 190 @Co-infection with ≥ 1 bacteria via nasopharyngeal fluid culture or PCR panel of 7 respiratory bacteria (*H. influenzae*, *S. pneumoniae*, *S. aureus*, *M. catarrhalis*, *M. pneumoniae*, *C. pneumoniae*, *L. pneumoniae*) or
 191 *Mycoplasma* antibody test.
 192
 193 \$@Any co-infection of ≥ 1 bacteria or viruses mentioned above.




194
 195 **Figure 1. Patient characteristics by lower respiratory illnesses.**

196 Upper panel: co-infection of human Adenovirus (HAdV) with other viruses or bacteria in patients with lower
 197 respiratory illnesses vs. those without.

198 Lower panel: some clinical features of patients with lower respiratory illnesses vs. those without.

199 Viral_coinfection: co-infection of HAdV with ≥ 1 other viruses in PCR panel or influenza virus type A or type B using
 200 rapid antigen test

201 Vacterial_coinfection: co-infection of HAdV with ≥ 1 bacteria via nasopharyngeal fluid culture or PCR panel of 7
 202 respiratory bacteria (H. influenzae, S. pneumonia, S. aureus, M. catarrhalis, M. pneumoniae, C. pneumoniae, L.
 203 pneumoniae) or Mycoplasma antibody test.
 204 Any_coinfection: co-infection of HAdV with ≥ 1 bacteria or viruses mentioned above.



205
 206 **Figure 2. Patient characteristics by severe pneumonia**

207 Upper panel: co-infection of human Adenovirus (HAdV) with other viruses or bacteria in patients with severe
 208 pneumonia vs. those without.
 209 Lower panel: some clinical features of patients with severe pneumonia vs. those without.
 210 viral_coinfection: co-infection of HAdV with ≥ 1 other viruses in PCR panel or influenza virus type A or type B using
 211 rapid antigen test
 212 bacterial_coinfection: co-infection of HAdV with ≥ 1 bacteria via nasopharyngeal fluid culture or PCR panel of 7
 213 respiratory bacteria (H. influenzae, S. pneumonia, S. aureus, M. catarrhalis, M. pneumoniae, C. pneumoniae, L.
 214 pneumoniae) or Mycoplasma antibody test.
 215 any_coinfection: co-infection of HAdV with ≥ 1 bacteria or viruses mentioned above.
 216

217

218 The mean (95%CI) age of all patients was 2.7 (2.4, 3) years and those with lower respiratory illnesses were
219 a bit younger than those without (mean (95%CI) = 2.3 (1.6, 2.9) vs. 3.1 (2.6, 3.6) respectively) and those
220 with severe pneumonia were the youngest (mean (95%CI) = 1.8 (0, 3.8)). Males accounted for 55% of all
221 patients and there were no gender bias in those with and without lower respiratory illnesses whereas 4/5
222 (80%) of those with severe pneumonia were males. About 43% of patients were born by Caesarean (C)-
223 section and the percentage was similar between those with and without lower respiratory illnesses while
224 4/5 (80%) of those with severe pneumonia were born by C_section (p=0.051). There was no difference in
225 BMI, gestational age, birth weight and duration of breastfeeding between those with and without lower
226 respiratory illnesses or between those with and without severe pneumonia (Table 1).

227 Day of illness at hospital visit of those with lower respiratory illnesses was later than those without (mean
228 (95%CI) = 4.7 (3.7, 5.6) days vs. 3.3 (2.8, 3.8) days (p=0.002)). Most of the patients had fever (94%) and
229 cough (84%) at disease onset. Most of the patients (79%) had high fever (>39 C) and long fever duration
230 (mean (95%CI) = 6.4 (5.7, 7.1) days). Poor eating (as compared to usual) as reported by caregivers was
231 found more in patients with lower respiratory illnesses than those without. There was no significant
232 difference in symptoms at disease onset such as cough, red eyes, diarrhea, fever maximal temperature,
233 fever duration, ear pain, etc as well as in hematology or biochemistry indexes between those with and
234 without lower respiratory illnesses or between those with and without severe pneumonia. Almost all
235 patients with lower respiratory illnesses (95%) had detectable abnormalities in chest X-rays as well as 16%
236 of those without lower respiratory symptoms (Table 1, Figure 1 and Figure 2).

237 About 25% of the patients with lower respiratory illnesses received oxygen supplements, about 10%
238 received IVIG, 44% received nebulizers, 24% received general steroids while none of the patients without
239 lower respiratory illnesses received these interventions. Duration of hospitalization was longer for those

240 with lower respiratory illnesses than those without (mean (95%CI) = 6.1 (4.7, 7.4) vs. 4.5 (3.8, 5.1) days)
241 and longest in those with severe pneumonia (mean (95%CI) = 9.5 (4.9, 14.1) days). All patients except one
242 were discharged without complication (Table 1, Figure 1 and 2).

243 The five patients with severe pneumonia were of a younger age and were predominantly male (80%), of
244 which 80% were born by C-section and were all co-infected with at least one other respiratory viruses or
245 bacteria ($p < 0.05$ as compared to other patients). There was no other remarkable difference in other
246 demographic, medical history or host characteristics as compared to other patients.

247 *Co-infection of HAdV and other respiratory viruses or bacteria*

248 Regarding viral co-infection, there were 19 (approx. 20%) samples tested positive for at least one other
249 virus from our respiratory virus PCR panel of which 5(5.1%) were co-infected with at least 2 viruses. The
250 number of samples co-infected with HEV, MPV, PIV1, PIV2, PIV3, PIV4 in the PCR panel were 7, 9, 4, 2, 0,
251 2 respectively. There were two samples co-infected with Influenza virus detected by rapid antigen test. In
252 overall, there were 20 samples co-infected with at least 1 virus detected by either PCR or rapid antigen
253 test. Regarding bacterial co-infection, there were 3, 11, 5 samples with positive culture for Streptococcus
254 pneumoniae, Haemophilus influenzae, Moraxella catarrhalis respectively. There were 2 patients with
255 blood antibody test positive for Mycoplasma pneumoniae. In overall, there were 20 patients co-infected
256 with at least one bacterium detected by either nasopharyngeal fluid culture or blood antibody test. There
257 were 5 patients co-infected with both at least one virus and at least one bacterium. In total, there were
258 35 patients co-infected with either virus or bacteria (Table 2).

259 **Table 2. Viral and bacterial co-infection in addition to human Adenovirus (HAdV).**

Viral co-infection	Any virus	HEV*	MPV*	PIV1*	PIV2*	PIV3*	PIV*4	Influenza#
Number of patients	20	7	9	4	2	0	2	1

Bacterial co-infection	Any bacteria	Streptococcus pneumoniae [§]	Haemophilus influenzae	Moraxella catarrhalis	Mycoplasma pneumoniae	Others		
Number of patients	20	3	11	5	2	0		
Viral and bacterial co-infection	Any virus and bacteria							
Number of patients	5							
Either viral or bacterial co-infection	Any virus or bacteria							
Number of patients	35							

260 *Viruses in the same PCR panel with human Adenovirus for nasal swab: HEV: human enterovirus, hMPV: human
 261 metapneumovirus, PIV1-4: parainfluenza virus 1-4.

262 #By rapid antigen test for nasal swab

263 §By culture of nasopharyngeal fluid

264 @By blood antibody test (IgM)

265 The percentage of samples co-infected with at least one other respiratory virus was significantly higher in
 266 patients with lower respiratory illnesses vs. those without (12 (50%) vs. 4 (9%), $p < 0.001$) and especially
 267 higher in those with severe pneumonia (4/5 (80%), $p=0.006$). Co-infection with at least one respiratory
 268 bacterium was detected in 20 (20.6%) patients, with 7 of these patients (29.2%) experiencing lower
 269 respiratory illnesses ($p=0.253$) and in 3 (60.0%) with severe pneumonia ($p=0.058$). Any co-infection with
 270 respiratory viruses or bacteria was found in 35 (36.1%) of all patients, significantly higher in those with
 271 lower respiratory illnesses (17 (70.8%), $p < 0.001$) and especially higher in those with severe pneumonia (5
 272 (100.0%), $p=0.005$) (Table 1, Table 2).

273 *Risk factors for lower respiratory illnesses and severe pneumonia*

274 Potential risk factors for lower respiratory illnesses or severe pneumonia which were clinically relevant
 275 and statistically significant from the above exploration were viral co-infection of HAdV with ≥ 1 respiratory
 276 viruses or bacterial co-infection of HAdV with ≥ 1 respiratory bacteria or any co-infection of HAdV with ≥ 1
 277 respiratory viruses or bacteria, age at hospital visit, sex, birth delivery method, day of disease at hospital
 278 visit. The results from univariate logistic regression and multivariate logistic regression adjusting for these
 279 factors in the models for the comparison between those with lower respiratory illnesses or severe
 280 pneumonia vs. those without are summarized in Table 3. Co-infection of HAdV with ≥ 1 other respiratory
 281 viruses was remarkably significantly associated with either lower respiratory illnesses or severe
 282 pneumonia (unadjusted OR (95%CI); (p-value) for those with lower respiratory illnesses or severe
 283 pneumonia vs. those without were 11.14 (3.77, 36.05); <0.0001 and 19.00 (2.60, 385.24); 0.0105
 284 respectively). After adjusting for age at hospital visit, sex, birth delivery method, day of disease at hospital
 285 visit, the association between co-infection and lower respiratory illnesses or severe pneumonia remained
 286 statistically significant (adjusted OR (95%CI); (p-value) for those with lower respiratory illnesses or severe
 287 pneumonia vs. those without were 7.4 (1.4, 52.1); 0.03 and 16.9 (1.8, 421.9); 0.03 respectively). Co-
 288 infection of HAdV with any respiratory viruses or bacteria was also remarkably significantly associated
 289 with lower respiratory illnesses (unadjusted OR (95%CI); (p-value) = 7.42 (2.75, 21.98); 0.0001 and
 290 adjusted OR (95%CI); (p-value) = 5.21 (1.60, 19.36); 0.0084).

291 **Table 3. Univariate and multivariate logistic regression of risk factors of lower respiratory illnesses or**
 292 **severe pneumonia.**

	Lower respiratory illnesses		Severe pneumonia	
Features	Univariate OR (95%CI); p-value*	Multivariate OR (95%CI); p-value**	Univariate OR (95%CI); p-value#	Multivariate OR (95%CI); p-value##

Viral co-infection\$ (yes vs. no)	11.14 (3.77, 36.05); <0.0001	10.74 (2.83, 48.17); 0.0009	19.00 (2.60, 385.24); 0.0105	19.44 (2.12, 492.73); 0.0207
Bacterial co- infection (yes vs. no)@	1.90 (0.63, 5.44); 0.2373	1.04 (0.26, 3.83); 0.9506	6.62 (1.02, 53.28); 0.0470	19.25 (1.74, 528.71); 0.0297
Any co-infection (yes vs. no)\$@	7.42 (2.75, 21.98); 0.0001	5.21 (1.60, 19.36); 0.0084	Inf (NA,NA); NA ###	Inf (NA,NA); NA ###
Age (year)	0.71 (0.48, 1.00); 0.0678	0.72 (0.41, 1.18); 0.2175	0.56 (0.24, 1.13); 0.1462	0.86 (0.32, 2.21); 0.7466
Sex (male vs. female)	0.92 (0.36, 2.35); 0.8531	0.52 (0.13, 1.86); 0.3226	3.35 (0.47, 66.86); 0.2884	1.46 (0.11, 37.77); 0.7823
Delivery method (vaginal vs. C- section)	0.42 (0.15, 1.17); 0.0964	0.45 (0.12, 1.63); 0.2235	0.12 (0.01, 0.87); 0.0642	0.11 (0.00, 1.14); 0.1002
Day of disease at hospital visit	1.46 (1.13, 1.95); 0.0060	1.48 (1.09, 2.13); 0.0204	1.10 (0.66, 1.63); 0.6483	1.21 (0.65, 2.10); 0.4884

293 *Comparison between those with and without lower respiratory illnesses. 95%CI from profile likelihood and p-
294 values from Wald test of univariate logistic regression model against each variable.

295 **Comparison between those with and without lower respiratory illnesses. 95%CI from profile likelihood and p-
296 values from Wald test for each variable in the multivariate logistic regression model. For viral co-infection or
297 bacterial co-infection or any co-infection, estimates are from the multivariate logistic regression model containing
298 either viral co-infection or bacterial co-infection or any co-infection and 4 other variables. For 4 other variables
299 (age, sex, delivery method, day of disease at hospital visit), estimates are from the multivariate logistic regression
300 model containing viral co-infection and these 4 variables..


301 # Comparison between those with and without severe pneumonia. 95%CI from profile likelihood and p-values from
302 Wald test of univariate logistic regression model against each variable.

303

304 *HAdV types and the relationship between HAdV types and clinical features*

305 Ninety-seven (98.98%) HAdV samples were genotyped successfully. BLAST results of 97 HAdV sequences
306 indicated that 82 (84.5%) samples belonged to subtype B3, 14 (14.4%) samples belonged to subtype C7
307 and 1 (1.0%) samples belonged to sybtype C2. The phylogenetic analysis were applied to compare 97
308 hexon gene sequences to each other and 24 reference sequences downloaded from GenBank

309 (Supplement Table 1). The phylogenetic tree of hexon gene confirmed the hexon sequences of HAdV
310 samples belonged to three distinguishable clusters of HAdV-B3, -B7 and C2 (Figure 3).




311

312 **Figure 3. Adenovirus types and phylogenetic tree.**

313 Neighbour-joining phylogenetic of the *hexon* gene of HAdV strains identified in patients hospitalized with respiratory
314 tract infections in Vinmec Times City Hospital between October and November 2022. The branch annotations
315 represent the bootstrap value calculated on 1000 replicates. White, green and red circles are corresponding to
316 sequences of HAdV references, HAdV specimens from non-severe patients and HAdV specimens from patients with
317 severe pneumonia.

318 Those infected with HAdV type 3 had higher WBC, higher neutrophil percentage and lower lymphocyte
319 percentage (mean (95%CI) of WBC, neutrophil %, lymphocyte % of those infected with HAdV type 3 vs.
320 type 7 were 16.2 (14.6, 17.8) vs. 9.4 (7.1, 11.7), 64.8 (61.6, 68) vs. 45.6 (39.2, 51.9), 23.3 (20.5, 26.2) vs.
321 41.9 (34.8, 49) respectively) ($p < 0.001$). In general, there was no remarkable difference in demographic,
322 medical history, disease manifestation or outcome features between patients infected with HAdV type 3,
323 7, 2_in this study except a significant difference in hematology test mentioned above (Figure 4).

324



325

326 **Figure 4. Clinical features by adenovirus types.**

327 Upper panel: some clinical features (lower respiratory illnesses (yes/ no), severe pneumonia (yes/ no),
328 duration of treatment) of three groups of patients infected with human Adenovirus (HAdV) type 2 vs. 3
329 vs. 7.

330 Lower panel: some hematological features (worst white blood cell (WBC) %, worst Neutrophil %, worst
331 lymphocyte %) of three groups of patients infected with human Adenovirus (HAdV) type 2 vs. 3 vs. 7.

332

333

334 Discussion

335 This study, to the best of our knowledge is probably the first providing a quick comprehensive snapshot
336 of both clinical features and molecular typing of the respiratory HAdV infection outbreak in children in
337 northern Vietnam in the end of 2022.

338 The predominant HAdV type in this study was species B type 3 (83%), followed by species B type 7 (16%)
339 and species C type 2 (1%). This is similar to the findings of other studies on circulating or outbreaks of
340 respiratory HAdV infections in children before the COVID-19 pandemic in Asia such as studies on
341 circulating respiratory HAdV in Hong Kong in 2014 (49), Taiwan from 2002 to 2013 (15), Guangzhou
342 China from 2017 to 2019 (27) or a study on febrile respiratory HAdV outbreaks in Hangzhou China in
343 2011 (17) or a study on successive respiratory HAdV outbreaks in Seoul, Korea from 1990 to 2000 (11).
344 Novel genome types were identified during the outbreaks of lower respiratory tract HAdV infection in
345 Seoul Korea and this 11-year study also suggested a genome type shift between successive outbreaks
346 (11). Therefore, further studies examining the genome types or variants of HAdV may be useful.

347 There was no significant association between the 3 HAdV types identified and clinical features in this
348 study, except that WBC and neutrophil numbers were higher in those infected with HAdV type 3 than with
349 type 7. The proportion of severe cases seemed to have similar distribution between the more
350 predominant HAdV type 3 and type 7. This is consistent with other previously published studies in which
351 HAdV type 3 and 7 were the most common types among more severe respiratory HAdV infections (10–
352 12,15–19).

353 Co-infections of HAdV with other respiratory viruses or bacteria stood out to be highly significantly
354 associated with increased severity of respiratory diseases. About 70.8% of those with lower respiratory
355 illnesses and 100% of those with severe pneumonia were co-infected with at least one respiratory viruses

356 or bacteria while the percentage was about 24.7% in those without lower respiratory illnesses. This
357 association remained statistically significant in a multivariate analysis adjusting for other potential risk
358 factors which were either clinically relevant or also statistically associated with lower respiratory illnesses
359 or severe pneumonia. This indicates that the association is both clinically meaningful and statistically
360 robust. This remarkable association suggests that HAdV might be the cause of the outbreak but might not
361 be the main cause of severe cases. Instead, the co-infection of other respiratory viruses or bacteria
362 together with HAdV might increase the severity of the disease. This advocates the advantage of multi-
363 factor respiratory PCR panel(s) for common respiratory viruses and probably also respiratory bacteria
364 together with other microbial tests such as culture for the diagnosis and prognosis of children with
365 respiratory infections. These results may be helpful for the diagnosis, treatment and prognosis of patients
366 in future outbreaks of respiratory HAdV infection.

367 Although the sample size of this study is limited, it is similar to those of many other previously published
368 studies analysing molecular typing for HAdV outbreaks (5,9,16,49–51). The study samples were from
369 pediatric patients of a private general hospital in Hanoi, Vietnam and molecular typing was performed
370 using samples with Ct for HAdV <30. As such, the study samples may not fully represent the general child
371 population of the outbreak. Additionally, it should be noted that clinical data were collected
372 retrospectively for samples with HAdV-positive PCR and thus some clinical data features maybe
373 incomplete, especially for outpatients. Moreover, molecular typing data may not be sufficient to
374 understand the characteristics of HAdV causing the outbreak and thus further study to examine HAdV
375 genome types or variants may be useful.

376 In summary, this study revealed that HAdV type 3 and type 7 were predominant in the current ongoing
377 outbreak of respiratory HAdV infection in children in northern Vietnam and HAdV type might not be
378 associated with the severity of the diseases. Instead, co-infection of HAdV together with other respiratory
379 viruses or bacteria appeared to be a significant risk factor for lower respiratory tract illnesses and severe

380 pneumonia. These findings advocate the advantages of multi-factor microbial panels for the diagnosis and
381 prognosis of respiratory infections in children. These results may be helpful for the diagnosis, treatment,
382 and prognosis of patients in future outbreaks of respiratory HAdV infection.

383

384 Notes

385 **Author Contributions.** D.D.N, L.T.T, H.T.T.T., and N.T.H. designed the study as well as drafted the initial
386 manuscript. N.T.H. led the data management and statistical analysis. All authors provided (1) additional
387 contributions to the conception or design of this work or the acquisition, analysis, or interpretation of
388 data for the work; (2) drafting of the manuscript or revising it critically for important intellectual
389 content; and (3) approval of the final version submitted. D.D.N., H.T.T.T., and N.T.H had full access to all
390 the data in the study and take responsibility for the integrity of the data and the accuracy of the data
391 analysis.

392 **Financial support.** This work was supported by the Research & Development fund of Vinmec High-tech
393 Centre, Vinmec Healthcare System.

394

395 References

- 396 1. Arnold A, MacMahon E. Adenovirus infections. *Medicine (United Kingdom)*. 2021.
- 397 2. CDC. Adenoviruses [Internet]. 2019 [cited 2022 Nov 17]. Available from:
398 <https://www.cdc.gov/adenovirus/index.html>
- 399 3. Gray GC, McCarthy T, Lebeck MG, Schnurr DP, Russell KL, Kajon AE, et al. Genotype prevalence and
400 risk factors for severe clinical adenovirus infection, United States 2004-2006. *Clin Infect Dis*. 2007;
- 401 4. Thounaojam AD, Balakrishnan A, Mun AB. Detection and molecular typing of human adenoviruses
402 associated with respiratory illnesses in Kerala. *Jpn J Infect Dis*. 2016;
- 403 5. Jin Y, Zhang RF, Xie ZP, Yan KL, Gao HC, Song JR, et al. Prevalence of adenovirus in children with
404 acute respiratory tract infection in Lanzhou, China. *Virology*. 2013;
- 405 6. Qurei L, Seto D, Salah Z, Azzeh M. A molecular epidemiology survey of respiratory adenoviruses
406 circulating in children residing in Southern Palestine. *PLoS One*. 2012;
- 407 7. Akello JO, Kamgang R, Barbani MT, Suter-Riniker F, Leib SL, Ramette A. Epidemiology of human
408 adenoviruses: A 20-year retrospective observational study in hospitalized patients in Bern,
409 Switzerland. *Clin Epidemiol*. 2020;
- 410 8. Duan Y, Xu B, Li C, Bao Y, An S, Zhou Y, et al. Molecular Characteristics of Human Adenovirus Type
411 3 Circulating in Parts of China During 2014–2018. *Front Microbiol*. 2021;
- 412 9. Yao LH, Wang C, Wei TL, Wang H, Ma FL, Zheng LS. Human adenovirus among hospitalized children
413 with respiratory tract infections in Beijing, China, 2017-2018. *Virology*. 2019;
- 414 10. Li Y, Zhou W, Zhao Y, Wang Y, Xie Z, Lou Y, et al. Molecular Typing and Epidemiology Profiles of
415 Human Adenovirus Infection among Paediatric Patients with Severe Acute Respiratory Infection in

- 416 China. Jin D-Y, editor. PLoS One. 2015 Apr 9;10(4):e0123234.
- 417 11. Kim Y-J, Hong J-Y, Lee H-J, Shin S-H, Kim Y-K, Inada T, et al. Genome Type Analysis of Adenovirus
418 Types 3 and 7 Isolated during Successive Outbreaks of Lower Respiratory Tract Infections in
419 Children. J Clin Microbiol. 2003 Oct;41(10):4594–9.
- 420 12. Xie L, Zhang B, Xiao N, Zhang F, Zhao X, Liu Q, et al. Epidemiology of human adenovirus infection
421 in children hospitalized with lower respiratory tract infections in Hunan, China. J Med Virol. 2019;
- 422 13. Li L, Phan TG, Nguyen TA, Kim KS, Seo JK, Shimizu H, et al. Molecular epidemiology of adenovirus
423 infection among pediatric population with diarrhea in asia. Microbiol Immunol. 2005;
- 424 14. Li F, Zhang Y, Shi P, Cao L, Su L, Zhang Y, et al. Epidemiology of Viruses Causing Pediatric Community
425 Acquired Pneumonia in Shanghai During 2010–2020: What Happened Before and After the COVID-
426 19 Outbreak? Infect Dis Ther. 2022;
- 427 15. Wang YF, Shen FC, Wang SL, Kuo PH, Tsai HP, Liu CC, et al. Molecular epidemiology and clinical
428 manifestations of adenovirus respiratory infections in taiwanese children. Med (United States).
429 2016;
- 430 16. Carballal G, Videla C, Misirlian A, Requeijo P V., del Carmen Aguilar M. Adenovirus type 7 associated
431 with severe and fatal acute lower respiratory infections in Argentine children. BMC Pediatr. 2002;
- 432 17. Xie L, Yu XF, Sun Z, Yang XH, Huang RJ, Wang J, et al. Two adenovirus serotype 3 outbreaks
433 associated with febrile respiratory disease and pharyngoconjunctival fever in children under 15
434 years of age in Hangzhou, China, during 2011. J Clin Microbiol. 2012;
- 435 18. Ghanaïem H, Averbuch D, Koplewitz BZ, Yatsiv I, Braun J, Dehtyar N, et al. An Outbreak of
436 Adenovirus Type 7 in a Residential Facility for Severely Disabled Children. Pediatr Infect Dis J. 2011
437 Nov;30(11):948–52.

- 438 19. Lin GL, Lu CY, Chen JM, Lee PI, Ho SY, Weng KC, et al. Molecular epidemiology and clinical features
439 of adenovirus infection in Taiwanese children, 2014. *J Microbiol Immunol Infect.* 2019;
- 440 20. Barrero PR, Valinotto LE, Tittarelli E, Mistchenko AS. Molecular typing of adenoviruses in pediatric
441 respiratory infections in Buenos Aires, Argentina (1999-2010). *J Clin Virol.* 2012;
- 442 21. Takahashi K, Gonzalez G, Kobayashi M, Hanaoka N, Carr MJ, Konagaya M, et al. Pediatric infections
443 by Human mastadenovirus C types 2, 89, and a recombinant type detected in Japan between 2011
444 and 2018. *Viruses.* 2019;
- 445 22. Çiçek C, Şanlıdağ T, Siyah Bilgin B, Pullukçu H, Akçali S, Altun Köroğlu Ö, et al. Molecular typing and
446 sequencing of adenovirus isolated from a conjunctivitis outbreak in a neonatal intensive care unit
447 by PCR. *Turkish J Med Sci.* 2012;
- 448 23. Engelmann I, Madisch I, Pommer H, Heim A. An outbreak of epidemic keratoconjunctivitis caused
449 by a new intermediate adenovirus 22/H8 identified by molecular typing. *Clin Infect Dis.* 2006;
- 450 24. Chang SY, Lee CN, Lin PH, Huang HH, Chang LY, Ko W, et al. A community-derived outbreak of
451 adenovirus type 3 in children in Taiwan between 2004 and 2005. *J Med Virol.* 2008;
- 452 25. Calvo C, García-García ML, Sanchez-Dehesa R, Román C, Tabares A, Pozo F, et al. Eight Year
453 Prospective Study of Adenoviruses Infections in Hospitalized Children. Comparison with Other
454 Respiratory Viruses. Costa C, editor. *PLoS One.* 2015 Jul 6;10(7):e0132162.
- 455 26. Lin MR, Yang SL, Gong YN, Kuo CC, Chiu CH, Chen CJ, et al. Clinical and molecular features of
456 adenovirus type 2, 3, and 7 infections in children in an outbreak in Taiwan, 2011. *Clin Microbiol
457 Infect.* 2017;
- 458 27. Wang X, Wang D, Umar S, Qin S, Ling Q, Gray GC, et al. Molecular typing of human adenoviruses
459 among hospitalized patients with respiratory tract infections in a tertiary Hospital in Guangzhou,

- 460 China between 2017 and 2019. BMC Infect Dis. 2021;
- 461 28. Zaki MES, Eid AR, Faried OA. Clinico-Pathological Study of Adenovirus Associated with Respiratory
462 Infections in Children. Open Microbiol J. 2020;
- 463 29. Zhu Y, Li W, Yang B, Qian R, Wu F, He X, et al. Epidemiological and virological characteristics of
464 respiratory tract infections in children during COVID-19 outbreak. BMC Pediatr. 2021;
- 465 30. Hsu HT, Huang FL, Ting PJ, Chang CC, Chen PY. The epidemiological features of pediatric viral
466 respiratory infection during the COVID-19 pandemic in Taiwan. J Microbiol Immunol Infect. 2021;
- 467 31. Li L, Wang H, Liu A, Wang R, Zhi T, Zheng Y, et al. Comparison of 11 respiratory pathogens among
468 hospitalized children before and during the COVID-19 epidemic in Shenzhen, China. Virol J. 2021;
- 469 32. Nguyen TTH, Le TA, Nguyen VH, Nguyen TU, Nguyen PT, Tran TTA, et al. Molecular typing of
470 conjunctivitis-causing adenoviruses in Hanoi, Vietnam from 2017 to 2019 and complete genome
471 analysis of the most prevalent type (HAdV-8). J Med Virol. 2020;
- 472 33. Jin XH, Ishiko H, Thanh Ha N, Ohguchi T, Akanuma M, Aoki K, et al. Molecular Epidemiology of
473 Adenoviral Conjunctivitis in Hanoi, Vietnam. Am J Ophthalmol. 2006;
- 474 34. Nguyen TA, Yagyu F, Okame M, Phan TG, Trinh QD, Yan H, et al. Diversity of viruses associated with
475 acute gastroenteritis in children hospitalized with diarrhea in Ho Chi Minh City, Vietnam. J Med
476 Virol. 2007;
- 477 35. Li L, Shimizu H, Doan LTP, Tung PG, Okitsu S, Nishio O, et al. Characterizations of adenovirus type
478 41 isolates from children with acute gastroenteritis in Japan, Vietnam, and Korea. J Clin Microbiol.
479 2004;
- 480 36. Le YH, Nguyen KC, Coleman KK, Nguyen TT, Than ST, Phan HH, et al. Virus detections among

- 481 patients with severe acute respiratory illness, Northern Vietnam. PLoS One. 2020;
- 482 37. Nguyen HK Le, Nguyen SV, Nguyen AP, Hoang PMV, Le TT, Nguyen TC, et al. Surveillance of severe
483 acute respiratory infection (SARI) for hospitalized patients in Northern Vietnam, 2011–2014. Jpn J
484 Infect Dis. 2017;
- 485 38. Alroy KA, Do TT, Tran PD, Dang TQ, Vu LN, Le NTH, et al. Expanding severe acute respiratory
486 infection (SARI) surveillance beyond influenza: The process and data from 1 year of
487 implementation in Vietnam. Influenza Other Respi Viruses. 2018;
- 488 39. Pham HT, Nguyen TNT, Tran QA, Ngo TT. Prevalence and associated factors with mixed coinfections
489 among under 5-year-old children with severe viral pneumonia in Vietnam. J Child Sci. 2020;
- 490 40. AH D, van Doorn HR, MN N, JE B, TH H, QH D, et al. Viral etiologies of acute respiratory infections
491 among hospitalized Vietnamese children in Ho Chi Minh City, 2004-2008. PLoS One. 2011;
- 492 41. Nguyen AT, Le N, Nguyen H, Tran T, Anscombe C, Lau C-Y, et al. Viral etiology of community-
493 acquired infection in Vietnam: unraveling the unknown by next-generation sequencing analysis.
494 Int J Infect Dis. 2019;
- 495 42. Yoshida LM, Suzuki M, Yamamoto T, Nguyen HA, Nguyen CD, Nguyen AT, et al. Viral pathogens
496 associated with acute respiratory infections in central vietnamese children. Pediatr Infect Dis J.
497 2010;
- 498 43. Wertheim HFL, Nadjm B, Thomas S, Agustiningsih, Malik S, Nguyen DNT, et al. Viral and atypical
499 bacterial aetiologies of infection in hospitalised patients admitted with clinical suspicion of
500 influenza in Thailand, Vietnam and Indonesia. Influenza Other Respi Viruses. 2015;
- 501 44. Hai LT, Thach HN, Tuan TA, Nam DH, Dien TM, Sato Y, et al. Adenovirus type 7 pneumonia in
502 children who died from measles-associated pneumonia, Hanoi, Vietnam, 2014. Emerg Infect Dis.

- 503 2016;
- 504 45. Hang LKN, Do LP, Van TTT, Nguyen SV, Hoang PVM, Pham HT, et al. Viral co-infections among
505 children with confirmed measles at hospitals in Hanoi, Vietnam, 2014. *Asian Pac J Trop Med.* 2017;
- 506 46. Huh HJ, Kim JY, Kwon HJ, Yun SA, Lee MK, Lee NY, et al. Performance evaluation of allplex
507 respiratory panels 1, 2, and 3 for detection of respiratory viruses and influenza a virus subtypes. *J*
508 *Clin Microbiol.* 2017;
- 509 47. Lee J, Lee HS, Cho YG, Choi SI, Kim DS. Evaluation of allplex respiratory panel 1/2/3 multiplex real-
510 time PCR assays for the detection of respiratory viruses with influenza a virus subtyping. *Ann Lab*
511 *Med.* 2018;
- 512 48. Lu X, Erdman DD. Molecular typing of human adenoviruses by PCR and sequencing of a partial
513 region of the hexon gene. *Arch Virol.* 2006;
- 514 49. Zhang J, Sridhar S, Lau SKP, Liu J, Ou J, Yan Y, et al. Molecular typing of human respiratory
515 adenoviruses with universal PCR and sequencing primers for three major capsid genes: Penton
516 base, hexon, and fiber. *bioRxiv.* 2020;
- 517 50. Marcone DN, Culasso ACA, Reyes N, Kajon A, Viale D, Campos RH, et al. Genotypes and
518 phylogenetic analysis of adenovirus in children with respiratory infection in Buenos Aires,
519 Argentina (2000–2018). *PLoS One.* 2021;
- 520 51. Dai H, Xi H, Huang L, Yuan Z, Liao Y, Tang Y, et al. Molecular epidemiology and clinical features
521 analysis of respiratory adenovirus infections reveals correlations between genotype, inflammatory
522 biomarkers, and disease severity. *Biomed Res Int.* 2020;
- 523